Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06512428 | A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 138 | Shanghai Runshi Pharmaceutical Technology Co., LtdINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06496789 | Neoadjuvant Serplulimab in Combination With Chemotherapy in Locally Advanced Gastric or Gastro-esophageal Junction Cancer | unknown | Phase 2 | 35 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 11, 2024 |
| clinicaltrials |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients(SOCRATE) | unknown | Phase 2 | 112 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | unknown | Phase 2 | 107 | Federation Francophone de Cancerologie DigestiveOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT05490719 | A Phase II Study of CRT Combined With QL1706 in ESCC Patients | unknown | Phase 2 | 39 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT03337087 | Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer | unknown | Phase 1 / Phase 2 | 18 | Academic and Community Cancer Research UnitedOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT04159974 | RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus(RICE) | unknown | Phase 2 | 56 | University of CologneOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06231680 | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | unknown | Phase 2 | 132 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 29, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT05512520 | Concurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）(EC-CRT-003) | unknown | Phase 2 | 126 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04999332 | Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer(LOTS) | unknown | Phase 2 | 58 | National Cheng-Kung University HospitalOTHER | 1 | Nov 15, 2023 | clinicaltrials |
| NCT06078657 | IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | unknown | Phase 2 | 120 | Chongqing University Cancer HospitalOTHER | 0 | Sep 26, 2023 | clinicaltrials |
| NCT05990231 | Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy | unknown | Phase 2 | 35 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 36 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Aug 24, 2023 | clinicaltrials |
| NCT05996484 | Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma | unknown | Phase 2 | 25 | Nanfang Hospital, Southern Medical UniversityOTHER | 0 | Aug 21, 2023 | clinicaltrials |
| NCT05235906 | A Phase II Clinical Study of Surufatinib Combined With Sintilimab in the Treatment of Advanced Gastric Cancer | unknown | Phase 2 | 61 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT05974059 | Cadonilimab Combined With CapeOX Regimen in Perioperative Treatment of Resectable Locally Advanced Gastric Cancer | unknown | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05281003 | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)(HYPERION) | unknown | Phase 2 | 128 | Fudan UniversityOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05896787 | Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jun 9, 2023 | clinicaltrials |
| NCT05038813 | Anlotinib Combined With TQB2450 (PD-L1 Inhibitor) in the Treatment of Advanced Esophageal Squamous Cell Carcinoma(ESCC) | unknown | Phase 2 | 46 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05865132 | Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal Junction | unknown | Phase 2 | 30 | AIPING ZHOUOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05833971 | Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 43 | Guangzhou Institute of Respiratory DiseaseOTHER | 0 | Apr 27, 2023 | clinicaltrials |
| NCT05818982 | To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC | unknown | Phase 2 | 72 | Peking UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT04389177 | Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001) | unknown | Phase 2 | 50 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT05791136 | Immunotherapy After Radiotherapy in Elderly ESCC(TREE) | unknown | Phase 2 | 30 | The Central Hospital of Lishui CityOTHER | 0 | Mar 30, 2023 | clinicaltrials |
| NCT05777707 | Neoadjuvant Therapy of PD-1 Blockade Combined With Chemotherapy for Esophageal Carcinoma | unknown | Phase 1 / Phase 2 | 89 | Beijing Friendship HospitalOTHER | 1 | Mar 21, 2023 | clinicaltrials |
| NCT05323890 | Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma. | unknown | Phase 2 | 15 | Shandong Cancer Hospital and InstituteOTHER | 1 | Mar 14, 2023 | clinicaltrials |
| NCT05163483 | Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer | unknown | Phase 2 | 87 | Ruihua XuOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03399071 | Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer(ICONIC) | unknown | Phase 2 | 44 | Royal Marsden NHS Foundation TrustOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05705635 | A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer | unknown | Phase 2 | 100 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） | unknown | Phase 2 | 50 | Shanghai Chest HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05636150 | A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 48 | Peking Union Medical College HospitalOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT04077255 | EGFR-targeted Therapy for Gastric Cancer | unknown | Phase 2 | 19 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05386056 | Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 54 | Peking UniversityOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05596890 | Patient-reported Outcomes in Preoperative Immunochemotherapy/Radiotherapy-treated Esophageal Cancer Patients(PICCRT) | unknown | Phase 2 | 50 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05594914 | AK104 Plus Concurrent Chemoradiation Therapy in Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 47 | The First Affiliated Hospital of University of South ChinaOTHER | 0 | Oct 26, 2022 | clinicaltrials |
| NCT05552651 | Envafolimab Combined With Chemotherapy in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 40 | Tao JiangOTHER | 0 | Sep 23, 2022 | clinicaltrials |
| NCT05541445 | Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC | unknown | Phase 1 / Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT05522894 | AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC | unknown | Phase 2 | 80 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 31, 2022 | clinicaltrials |
| NCT04699994 | Prospective Trial to Evaluate the Safety and Efficacy to Treat Esophageal Cancer Using 5-FU, Oxaliplatin, and Docetaxel | unknown | Phase 2 | 60 | Keio UniversityOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT05170256 | Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients(HERES) | unknown | Phase 2 | 24 | Morten Mau-SørensenOTHER | 1 | Aug 12, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jul 22, 2024source: clinicaltrials